Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AURANASDAQ:TKNONASDAQ:TRDANASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$6.10-0.7%$5.64$4.35▼$12.38$306.64M0.42207,829 shs166,412 shsTKNOAlpha Teknova$5.77-0.3%$5.97$1.16▼$10.37$308.36M0.4399,437 shs411,111 shsTRDAEntrada Therapeutics$8.12+2.4%$8.25$7.10▼$21.79$308.18M0.04132,648 shs107,234 shsUNCYUnicycive Therapeutics$0.77-0.7%$0.59$0.20▼$0.87$92.79M2.141.60 million shs3.54 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences-3.00%+2.33%+3.72%-17.80%-14.60%TKNOAlpha Teknova+0.70%-0.17%-3.66%+1.05%+212.97%TRDAEntrada Therapeutics-3.76%+2.06%-12.76%-23.90%-48.17%UNCYUnicycive Therapeutics+1.57%+26.86%+19.65%+40.78%-3.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAURAAura Biosciences2.6451 of 5 stars3.61.00.00.03.93.30.0TKNOAlpha Teknova1.99 of 5 stars3.51.00.00.03.20.80.6TRDAEntrada Therapeutics2.5837 of 5 stars3.62.00.00.01.81.71.3UNCYUnicycive Therapeutics3.5528 of 5 stars3.85.00.00.03.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAURAAura Biosciences 3.25Buy$22.00260.66% UpsideTKNOAlpha Teknova 3.00Buy$8.5047.31% UpsideTRDAEntrada Therapeutics 3.25Buy$25.67216.09% UpsideUNCYUnicycive Therapeutics 3.50Strong Buy$6.00680.03% UpsideCurrent Analyst Ratings BreakdownLatest UNCY, AURA, TRDA, and TKNO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$22.005/27/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$9.005/23/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$19.005/20/2025TRDAEntrada TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/21/2025UNCYUnicycive TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.004/11/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.50 ➝ $7.504/1/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $7.503/31/2025TRDAEntrada TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/26/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$19.003/26/2025AURAAura BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/25/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$25.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAURAAura BiosciencesN/AN/AN/AN/A$4.58 per shareN/ATKNOAlpha Teknova$38.25M8.06N/AN/A$2.21 per share2.61TRDAEntrada Therapeutics$172.22M1.79N/AN/A$7.26 per share1.12UNCYUnicycive Therapeutics$680K136.45N/AN/A($0.11) per share-6.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAURAAura Biosciences-$76.41M-$1.90N/AN/AN/AN/A-41.57%-36.43%8/14/2025 (Estimated)TKNOAlpha Teknova-$36.78M-$0.48N/AN/AN/A-87.17%-35.30%-24.52%N/ATRDAEntrada Therapeutics-$6.68M$0.815.11N/AN/A25.53%16.11%10.39%8/12/2025 (Estimated)UNCYUnicycive Therapeutics-$30.54M-$0.51N/AN/AN/AN/AN/A-29.88%N/ALatest UNCY, AURA, TRDA, and TKNO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025AURAAura Biosciences-$0.47-$0.55-$0.08-$0.55N/AN/A5/14/2025Q1 2025UNCYUnicycive Therapeutics-$0.14-$0.05+$0.09-$0.05N/AN/A5/8/2025Q1 2025TKNOAlpha Teknova-$0.11-$0.09+$0.02-$0.09$9.41 million$9.60 million5/8/2025Q1 2025TRDAEntrada Therapeutics-$0.78-$0.42+$0.36-$0.42$10.98 million$8.75 million3/27/2025Q4 2024UNCYUnicycive Therapeutics-$0.13-$0.26-$0.13-$0.26N/AN/A3/24/2025Q4 2024AURAAura Biosciences-$0.43-$0.52-$0.09-$0.52N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAURAAura BiosciencesN/AN/AN/AN/AN/ATKNOAlpha TeknovaN/AN/AN/AN/AN/ATRDAEntrada TherapeuticsN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAURAAura BiosciencesN/A12.4712.47TKNOAlpha Teknova0.124.733.94TRDAEntrada TherapeuticsN/A6.596.59UNCYUnicycive TherapeuticsN/A3.613.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAURAAura Biosciences96.75%TKNOAlpha Teknova13.81%TRDAEntrada Therapeutics86.39%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipAURAAura Biosciences5.40%TKNOAlpha Teknova12.50%TRDAEntrada Therapeutics8.11%UNCYUnicycive Therapeutics10.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAURAAura Biosciences5050.27 million47.25 millionNot OptionableTKNOAlpha Teknova24053.44 million45.21 millionNot OptionableTRDAEntrada Therapeutics11037.95 million34.58 millionOptionableUNCYUnicycive Therapeutics9120.63 million78.78 millionNot OptionableUNCY, AURA, TRDA, and TKNO HeadlinesRecent News About These CompaniesUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Sees Significant Drop in Short InterestJune 3 at 7:49 AM | marketbeat.comQ2 Earnings Estimate for UNCY Issued By HC WainwrightMay 31, 2025 | americanbankingnews.comWhat is HC Wainwright's Estimate for UNCY Q2 Earnings?May 30, 2025 | marketbeat.comQ4 Earnings Estimate for UNCY Issued By HC WainwrightMay 29, 2025 | marketbeat.comUnicycive Therapeutics (NASDAQ:UNCY) Raised to Strong-Buy at HC WainwrightMay 29, 2025 | americanbankingnews.comUnicycive Therapeutics' (UNCY) "Buy" Rating Reiterated at HC WainwrightMay 28, 2025 | marketbeat.comUnicycive Therapeutics CEO Shalabh Gupta to Present at Upcoming Investor ConferencesMay 22, 2025 | quiverquant.comUnicycive Therapeutics to Present at Upcoming Investor ConferencesMay 22, 2025 | globenewswire.comUnicycive Therapeutics Announces Time Change for 2025 Annual Meeting of StockholdersMay 21, 2025 | globenewswire.comQ2 Earnings Forecast for UNCY Issued By Noble FinancialMay 20, 2025 | marketbeat.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Shares Acquired by Octagon Capital Advisors LPMay 15, 2025 | marketbeat.comUnicycive Therapeutics, Inc.: Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | finanznachrichten.deUnicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | globenewswire.comAlyeska Investment Group L.P. Trims Stock Holdings in Unicycive Therapeutics, Inc. (NASDAQ:UNCY)May 9, 2025 | marketbeat.comAnalysts Expect Breakeven For Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Before LongMay 7, 2025 | finance.yahoo.comUnicycive Therapeutics (UNCY) to Release Quarterly Earnings on MondayMay 7, 2025 | marketbeat.comGuggenheim Initiates Coverage of Unicycive Therapeutics (UNCY) with Buy RecommendationApril 22, 2025 | msn.comUnicycive Therapeutics initiated with a Buy at GuggenheimApril 22, 2025 | markets.businessinsider.comUnicycive presents new patient-level data from Phase 2 study of OLCApril 12, 2025 | markets.businessinsider.comUnicycive Therapeutics price target raised to $7.50 from $4 at H.C. WainwrightApril 2, 2025 | markets.businessinsider.comNoble Financial Sticks to Their Buy Rating for Unicycive Therapeutics (UNCY)April 2, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUNCY, AURA, TRDA, and TKNO Company DescriptionsAura Biosciences NASDAQ:AURA$6.10 -0.04 (-0.65%) Closing price 04:00 PM EasternExtended Trading$6.01 -0.09 (-1.46%) As of 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Alpha Teknova NASDAQ:TKNO$5.77 -0.02 (-0.35%) Closing price 04:00 PM EasternExtended Trading$5.78 +0.01 (+0.09%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.Entrada Therapeutics NASDAQ:TRDA$8.12 +0.19 (+2.40%) Closing price 04:00 PM EasternExtended Trading$8.12 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Unicycive Therapeutics NASDAQ:UNCY$0.77 -0.01 (-0.75%) Closing price 04:00 PM EasternExtended Trading$0.78 +0.01 (+1.66%) As of 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
